ArticleWorld journal of urology2026
Extended-course transcutaneous tibial nerve stimulation for pediatric overactive bladder: a 6-Month prospective single-arm study.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo estimate the added clinical benefit of extending transcutaneous tibial nerve stimulation (TTNS) from 12 to 24 weeks in pediatric overactive bladder (OAB), and to characterize late responders. PATIENTS AND
methodsProspective single-arm cohort with home-based TTNS and assessments at baseline, 12, and 24 weeks. The primary outcome was change in OAB Symptom Score (OABSS) and responder status defined by a minimal clinically important difference (MCID) of≥3 points. Paired responder transitions were tested with McNemar's exact test and summarized as paired risk difference (RD) with 10,000-sample bootstrap 95% CIs; repeated-measures GEE/LMM were pre-specified for confirmatory modeling.
resultsAmong 80 paired observations, 12→24-week transitions were 0→0: 13, 0→1: 14, 1→0: 0, 1→1: 53. The paired RD in responder rate (24w-12w) was 0.175 (95% CI 0.100-0.263; McNemar p=0.000122). Late response occurred in 14 of 27 (51.9%) 12-week nonresponders. Mean OABSS improved by 3.64±2.25 at 12 weeks and 5.14±2.63 at 24 weeks.
conclusionsExtending TTNS to 24 weeks was associated with additional symptom improvement and a substantial proportion of late responders without loss of response. Findings suggest that continuing TTNS beyond 12 weeks may be considered for early nonresponders, pending confirmation in randomized, sham-controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.